Nosso grupo organiza mais de 3.000 Séries de conferências Eventos todos os anos nos EUA, Europa e outros países. Ásia com o apoio de mais 1.000 Sociedades e publica mais de 700 Acesso aberto Periódicos que contém mais de 50.000 personalidades eminentes, cientistas de renome como membros do conselho editorial.

Periódicos de acesso aberto ganhando mais leitores e citações
700 periódicos e 15 milhões de leitores Cada periódico está obtendo mais de 25.000 leitores

Abstrato

Artificial Intelligence to Improve Drug Safety and Toxicology

Lora L Cncela

The field of drug safety and toxicology is vital for ensuring the safety and effectiveness of pharmaceutical products. However, traditional approaches to drug safety assessment and toxicological studies are often resource-intensive, timeconsuming, and reliant on animal testing, presenting ethical concerns. In recent years, artificial intelligence (AI) has emerged as a promising solution to revolutionize drug safety and toxicology research. This dissertation aims to explore the applications of AI in enhancing drug safety and toxicology, examine the associated challenges and limitations, and propose potential solutions for future advancements. The study will provide an overview of AI techniques, including machine learning, deep learning, and natural language processing, and their relevance to drug safety and toxicology. It will assess the benefits and challenges of implementing AI in this field, such as improved predictive modeling of drug toxicity, computational models for pharmacokinetics and pharmacodynamics, drug repurposing, and detection of adverse drug reactions. Additionally, ethical considerations, data availability and quality, and regulatory and legal implications will be discussed. The dissertation will conclude with future perspectives, recommendations, and the potential impact of AI on drug safety and toxicology research, ultimately contributing to the advancement of this critical field.

Isenção de responsabilidade: Este resumo foi traduzido usando ferramentas de inteligência artificial e ainda não foi revisado ou verificado.